OmniAb (OABI) Projected to Post Quarterly Earnings on Thursday

OmniAb (NASDAQ:OABI) is anticipated to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $5.60 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

OmniAb (NASDAQ:OABI) last issued its earnings results on Wednesday, March 4th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $8.38 million for the quarter, compared to analyst estimates of $9.00 million. OmniAb had a negative return on equity of 23.99% and a negative net margin of 347.04%. On average, analysts expect OmniAb to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Stock Down 1.8%

Shares of NASDAQ:OABI traded down $0.03 on Tuesday, reaching $1.39. 172,730 shares of the company’s stock were exchanged, compared to its average volume of 399,632. The firm has a market capitalization of $200.52 million, a price-to-earnings ratio of -2.43 and a beta of 0.07. OmniAb has a fifty-two week low of $1.22 and a fifty-two week high of $2.30. The business’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.74.

Analysts Set New Price Targets

A number of brokerages have weighed in on OABI. Wall Street Zen raised shares of OmniAb from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Benchmark reissued a “buy” rating on shares of OmniAb in a report on Friday, March 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, OmniAb currently has a consensus rating of “Hold” and an average price target of $4.50.

Insider Buying and Selling

In related news, CEO Matthew W. Foehr sold 19,244 shares of the firm’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $1.49, for a total value of $28,673.56. Following the sale, the chief executive officer directly owned 4,420,492 shares in the company, valued at $6,586,533.08. This trade represents a 0.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 117,703 shares of company stock valued at $193,597. 8.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On OmniAb

Several large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its stake in OmniAb by 20.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock valued at $78,000 after buying an additional 7,624 shares during the period. Rhumbline Advisers increased its stake in OmniAb by 6.0% during the 2nd quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock valued at $280,000 after buying an additional 9,163 shares during the period. Osaic Holdings Inc. increased its stake in OmniAb by 214.4% during the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after buying an additional 9,716 shares during the period. AQR Capital Management LLC acquired a new position in OmniAb during the 1st quarter valued at about $25,000. Finally, BNP Paribas Financial Markets increased its stake in OmniAb by 92.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after buying an additional 10,438 shares during the period. Institutional investors and hedge funds own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.